EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Rongzhen Li, Xiaoyan Liu, Yan Xu iD, Jing Zhao, Wei Zhong, Xiaoxing Gao, Minjiang Chen iD, Mengzhao Wang

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15459 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Rongzhen Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Med…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Mutation, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesenchymal–epithelial transition ( MET ) exon 14 ( MET ex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating MET ex14 skipping‐mutated NSCLC. However, its feasibility for perioperative application remains unclear. This report describes a 60‐year‐old man with stage IIIA (cT2N2M0) lung adenocarcinoma harboring a MET ex14 skipping mutation. After initial treatment with savolitinib was discontinued due to grade 4 transaminitis, the patient was switched to tepotinib, resulting in significant tumor regression. Six months later, further shrinkage was observed, and surgery revealed remarkable pathological response with no residual tumor in lymph nodes (ypT2N0M0, IB). Postoperative tepotinib continued, with no relapse at 6‐month follow‐up. This case highlights the potential of tepotinib as neoadjuvant therapy for resectable MET ex14 skipping‐mutated NSCLC, warranting further clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsMutationProto-Oncogene Proteins c-metNeoadjuvant TherapyExonsHumansMaleMiddle AgedPyrimidinesPiperidinesPyridazines

Stichwörter der Autor:innen

MET exon 14 skipping mutationneoadjuvantnon‐small cell lung cancertepotinib

Substanzen

tepotinibProto-Oncogene Proteins c-metMET protein, humanPyrimidinesPiperidinesPyridazines

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Yan Xu, Minjiang Chen

Förderung

  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Li, R., Liu, X., Xu, Y., Zhao, J., Zhong, W., Gao, X., Chen, M., & Wang, M. (2024). Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15459

Vancouver

Li R, Liu X, Xu Y, Zhao J, Zhong W, Gao X, et al. Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15459

BibTeX
@article{Li2024,
  author = {Li, Rongzhen and Liu, Xiaoyan and Xu, Yan and Zhao, Jing and Zhong, Wei and Gao, Xiaoxing and Chen, Minjiang and Wang, Mengzhao},
  title = {Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15459}
}
Kostenlos starten →